The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Hypothesis: Progesterone Primes Breast Cancer Cells for Cross-Talk with Proliferative or Antiproliferative Signals
Abstract
In the breast, data from numerous laboratories suggest that cross-talk exists between PR and growth factor and cytokine signaling pathways at multiple levels (Fig. 4). At the cell surface (level 1), progestins up-regulate growth factor and cytokine receptors. We have expanded this observation by examining the effects of progestins in the cytoplasm (level 2) where progestins regulate several intracellular effectors by increasing the levels and altering the subcellular compartmentalization of Stat5, increasing the association of Stat5 with phosphotyrosine-containing proteins and tyrosine phosphorylation of JAK2, Cbl, and Shc, and potentiating EGF-stimulated p42/p44 MAPKs, p38 MAP kinase, and JNK activities. Together, these events lead to sensitization of downstream signaling pathways to the actions of locally acting secondary factors. Finally, inside the nucleus (level 3), agonist-occupied PR synergize with nuclear transcription factors that are growth-factor regulated, to control the activity of key genes involved in breast cell fate (Figs. 1 and 4). We speculate that after progesterone treatment, orchestrated combinations of steroid hormones and growth factors or cytokines can fine tune the timing and degree of expression of a subset of genes that determine whether progestin-primed cells undergo proliferation, differentiation, or programmed cell death. The paradoxical effects of progesterone have presented a longstanding conundrum to the scientist and clinician. Why are physiological levels of progesterone proliferative in the breast but antiproliferative and protective in the uterus? If progesterone is proliferative in the breast, why is high-dose progestin therapy successful in treating breast cancer? Our intent here has been to open a dialogue addressing these questions. Our data and that of others are beginning to show that one cannot approach the question of progestin actions in isolation. Other important regulatory proteins, whose expression may vary in tissue-specific ways, work in concert with progesterone to decide cell fate. The timing and dose of progesterone may also influence the biological response. Since progestins are widely used in oral contraception, in hormone replacement therapy, and in cancer treatments, it is becoming critically important that the subtleties of their mechanisms of action be clearly understood.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New functional activities for the p21 family of CDK inhibitors.
LaBaer, J., Garrett, M. D., Stevenson, L. F., Slingerland, J. M., Sandhu, C., Chou, H. S., Fattaey, A., & Harlow, E. (1997) · Genes & Development · doi:10.1101/gad.11.7.847 · Cited by 1,402
Functional interactions between Stat5 and the glucocorticoid receptor
Stöcklin, E., Wissler, M., Gouilleux, F., & Groner, B. (1996) · Nature · doi:10.1038/383726a0 · Cited by 675
Progestin regulation of cellular proliferation.
CLARKE, C. L., & SUTHERLAND, R. L. (1990) · Endocrine Reviews · doi:10.1210/edrv-11-2-266 · Cited by 650
Wyszomierski, S. L., Yeh, J., & Rosen, J. M. (1999) · Molecular Endocrinology · doi:10.1210/mend.13.2.0232 · Cited by 124
Cited by
MAPK signal pathways in the regulation of cell proliferation in mammalian cells
ZHANG, W., & LIU, H. T. (2002) · Cell Research · doi:10.1038/sj.cr.7290105 · Cited by 2,845
Endocrine-responsive breast cancer and strategies for combating resistance
Ali, S., & Coombes, R. C. (2002) · Nature Reviews Cancer · doi:10.1038/nrc721 · Cited by 883
Boonyaratanakornkit, V., Scott, M. P., Ribon, V., Sherman, L., Anderson, S. M., Maller, J. L., Miller, W. T., & Edwards, D. P. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00304-5 · Cited by 589
Arpino, G., Wiechmann, L., Osborne, C. K., & Schiff, R. (2008) · Endocrine Reviews · doi:10.1210/er.2006-0045 · Cited by 549
Kaaks, R., Berrino, F., Key, T., Rinaldi, S., Dossus, L., Biessy, C., Secreto, G., Amiano, P., Bingham, S., Boeing, H., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji132 · Cited by 420
Metadata
- Authors
- Lange, C. A., Richer, J. K., & Horwitz, K. B.
- Venue
- Molecular Endocrinology
- Publisher
- The Endocrine Society
- Published
- 1999-06
- Volume
- 13
- Issue
- 6
- Pages
- 829-836
- ISSN
- 0888-8809 (ISSN-L)
- 1944-9917
- OpenAlex
- W2114383291
- Cited by
- 181
- References
- 4
- FWCI
- 6.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hypothesis: Progesterone Primes Breast Cancer Cells for Cross-Talk with Proliferative or Antiproliferative Signals. https://app.cochat.ai/papers/10.1210/mend.13.6.0290
- The paper
- Lange, C. A., Richer, J. K., & Horwitz, K. B. (1999). Hypothesis: Progesterone Primes Breast Cancer Cells for Cross-Talk with Proliferative or Antiproliferative Signals. Molecular Endocrinology. https://doi.org/10.1210/mend.13.6.0290
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.